Clinical Trial Update: TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)

View source ↗

Summary

This document reports the completion of the TE-Prove post-approval surveillance study evaluating the TAXUS Element paclitaxel-eluting coronary stent system in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Element Paclitaxel-Eluting Coronary Stent System (paclitaxel-eluting coronary stent system)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Heart Disease | Status: COMPLETED